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ABBREVIATIONS DEFINITION LIST 
 
NO  Nitric oxide 
BP  Blood pressure 
HDL  High-density lipoprotein 
LDL  Low-density lipoprotein 
HOMA  Homeostatic Model Assessment 
IR  Insulin Resistance 
ABPM  Ambulatory Blood Pressure Monitoring 
FMD  Flow-mediated dilation 
PAT  Peripheral arterial tonometry 
PWV  Pulse wave velocity 
DT  Distance travelled 
TT  Transit time 
MAP  Mean arterial pressure 
AP  Augmentation pressure 
Aix  Augmentation index 
IMT  Intima-media thickness 
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Condensed Abstract 
 
This study evaluated the effects of magnesium supplementation on blood pressure (BP) 
and vascular function in thiazide-treated hypertensive women, mean 24-h BP≥130/80 
mmHg, in a randomized, double-blind, clinical trial comparing placebo and magnesium 
chelate 600 mg/day supplementation. Brachial flow-mediated dilatation (FMD) and 
central hemodynamic parameters were measured at inclusion and after 6 months. The 
magnesium group demonstrated a significant reduction in systolic and diastolic BP, and 
a significant increase in variation of FMD versus the placebo group (+3.7±2.1 vs 
2.4±1.2 %, p=0.015). In conclusion, magnesium supplementation was associated with 
better BP control and improved endothelial function in thiazide-treated hypertensive. 
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Abstract 
 
Epidemiological studies demonstrate an inverse association between serum magnesium 
and incidence of cardiovascular disease. Diuretics commonly cause hypomagneseamia. 
We evaluated effects of magnesium supplementation on blood pressure (BP) and 
vascular function in thiazide-treated hypertensive women in a randomized, double-
blind, clinical trial. Hypertensive women (40- 65 years)- on hydrochlorothiazide and  
mean 24-h BP≥130/80 mmHg were divided into placebo and supplementation 
(magnesium chelate 600 mg/day) groups. Patients were evaluated for nutritional and 
biochemical parameters, office and ambulatory blood pressure monitoring (ABPM), 
brachial flow-mediated dilatation (FMD), peripheral arterial tonometry, assessment of 
carotid intima-media thickness (IMT), central hemodynamic parameters and pulse wave 
velocity at inclusion and after 6-month follow-up. The magnesium group had a 
significant reduction in systolic BP (144±17 vs 134±14mmHg, p=0.036) and diastolic 
BP (88±9 vs 81±8mmHg, p=0.005) at 6 months, without effect on plasma glucose, 
lipids or arterial stiffness parameters. The placebo group showed a significant increase 
in carotid IMT (0.78±0.13 vs 0.89±0.14mm, p=0.033) without change in the magnesium 
group (0.79±0.16 vs 0.79±0.19mm, p=0.716) after 6 months. The magnesium group 
demonstrated a significant increase in variation of FMD versus the placebo group 
(+3.7±2.1 vs 2.4±1.2 %, p=0.015). There was a significant correlation between the 
intracellular magnesium variation and FMD (r=0.44, p=0.011). In conclusion, 
magnesium supplementation was associated with better BP control, improved 
endothelial function and amelioration of subclinical atherosclerosis in these thiazide-
treated hypertensive women. 
Keywords: hypertension; endothelial dysfunction; flow-mediated dilation; magnesium; 
arterial stiffness; pulse wave velocity 
Introduction 
Many factors have been implicated in the pathogenesis of hypertension, such as 
activation of the renin-angiotensin-aldosterone system and intracellular changes in ions 
like calcium, sodium, potassium and magnesium [1], [2], [3]. Magnesium has been the 
subject of experimental and clinical studies in hypertension [4-8] on the background that 
epidemiological studies showed significant inverse correlation between serum 
magnesium levels and incidence of cardiovascular disease [9] [10, 11].  
Magnesium is the second most abundant intracellular cation and is involved in 
several important biochemical reactions [12]. Magnesium regulates vascular tone, by 
influencing formation and release of nitric oxide (NO), and competing against effects of 
calcium resulting in changes in the vascular smooth muscle tone and contractility [13, 
14]. In addition, magnesium deficiency has previously been related to oxidative stress, 
inflammation, endothelial dysfunction, platelet aggregation, insulin resistance and 
hyperglycemia [15-19]  
Hypomagnesemia has been shown to negatively influence functional and 
structural vascular alterations in hypertension [20] but the influence on arterial stiffness 
has not yet been demonstrated been. Hypomagnesemia has been implicated in the 
pathogenesis of high blood pressure (BP), endothelial dysfunction, dyslipidemia and 
inflammation [21-23], with these factors being associated with arterial stiffness [24, 25]. 
Furthermore, epidemiological studies indicate a direct relationship between 
atherosclerosis and low serum magnesium [26], probably associated with insufficient 
dietary intake of this mineral [27]. In addition to reduced dietary intake of magnesium, 
drugs, such as thiazide diuretics, also lead to hypomagneseamia. Whether patients treated 
with such drugs have associated vascular damage remains unclear. Thus, the aim of this 
study was to evaluate the effects of 6-month magnesium supplementation on functional 
and structural vascular changes as well as blood pressure control in hypertensive women 
treated with diuretics. 
 
Methods 
Study Population 
A double-blind randomized clinical trial was carried out to evaluate women with 
uncontrolled hypertension, aged 40–65 years, on stable monotherapy with 
hydrochlorothiazide 25 mg at least in the last 4 weeks. Exclusion criteria were BP ≥ 
160/100 mmHg, body mass index≥ 35 kg/m2, diabetes mellitus, kidney disease, clinical 
evidence of heart failure, coronary artery disease and previous stroke. Participants were 
randomized to receive placebo or 600 mg of magnesium chelate orally twice a day for 6 
months. Clinical evaluation, laboratory tests and vascular studies were performed before 
and after the 6-month intervention period. The local ethics committee approved the 
protocol, and all subjects gave their written informed consent. This study was registered 
at ClinicalTrials.gov (NCT01151683). 
 
Biochemical evaluation 
Venous blood samples were collected after 12 hours of fasting. Serum lipids 
(total cholesterol, high-density lipoprotein [HDL]-cholesterol, triglycerides), and blood 
glucose were measured using an auto analyzer technique (Technicon DAX 96; Miles 
Inc). Low-density lipoprotein (LDL)-cholesterol was calculated with the Friedewald 
formula when triglyceride values were <400 mg/dl. Serum magnesium was measured 
by colorimetry and intracellular (intra erythrocyte) magnesium was evaluated by atomic 
absorption spectrometry. Insulin was measured by radioimmunoassay, and the 
Homeostatic Model Assessment – Insulin Resistance (HOMA-IR) index [fasting 
glucose (mmol/l) x fasting insulin (mUI/ml)/22.5] and HOMA-beta [fasting insulin x 
20/(fasting glucose – 3.5)] were calculated to estimate insulin sensitivity and secretion 
[28]. 
Ambulatory Blood Pressure Monitoring 
The patients underwent 24-hour ambulatory blood pressure monitoring (ABPM) 
in non-dominant arm with SpaceLabs 90207 monitor (Spacelabs Inc., Redmond, WA, 
USA), validated by the British Hypertension Society and the Association for the 
Advancement of Medical Instrumentation protocol [29]. Readings were taken every 20 
minutes during the day and every 30 minutes at night. The patients recorded their sleep 
and wake times during the monitoring. ABPM was considered adequate if >70% of 
measurements were successfully obtained. The percentage decline in nocturnal blood 
pressure was calculated as follows for systolic and diastolic BP: % BP fall = [(daytime 
BP−night-time BP) /daytime BP]* 100. 
 
Assessment of endothelial function 
Flow-mediated dilation (FMD) was assessed as a measure of endothelial 
function. The participant was positioned supine with the arm in a comfortable position, 
and the brachial artery was imaged above the antecubital fossa. After 10 minutes of rest, 
the right brachial artery was scanned in longitudinal section, 5 cm above the antecubital 
fossa, using a linear array transducer to acquire the baseline diameter of the brachial 
artery. A cuff was then inflated to at least 50 mmHg above systolic BP and deflated 
after 5 minutes to induce reactive hyperemia. A pulse wave Doppler recording in the 
artery lumen documented the flow increase, and the maximal diameter after cuff release 
was registered. FMD was calculated as the maximal percentage change of brachial 
artery diameter from baseline. 
 Peripheral arterial tonometry (PAT) 
Endothelial function was also evaluated in microcirculation with the Endo-PAT 
system (Itamar Medical Ltd, Caesarea, Israel). During the measurement, the subjects 
remained in a chair with their hands at the level of their heart and fingers hanging 
freely. Fingertip probes were placed on both index fingers, and pulse wave amplitudes 
were detected and recorded during the study. After a 5-minute baseline measurement, 
arterial flow was occluded with a cuff on the non-dominant arm. After 5 minutes of 
occlusion, the cuff was rapidly deflated to allow reactive hyperemia. Pulse wave 
amplitudes were recorded again for at least 5 minutes. The software calculated a 
reactive hyperemia index, which was a ratio of the average pulse wave amplitude 
measured over 60 seconds, starting 1 minute after cuff deflation, to the average pulse 
wave amplitude measured at the baseline. The other arm served as a control, and the 
ratio was corrected for changes in the systemic vascular tone. 
 
Pulse wave velocity 
The same investigator using a Complior device (Alam Medical, France) after the 
patients had rested for 10 minutes in supine position in a quiet room with a stable 
temperature measured carotid-femoral pulse wave velocity (PWV). All measurements 
were performed between 8 a.m. and 11a.m. During the measurements, speaking or 
sleeping was not allowed and no meal, caffeine or smoking was allowed within 3h 
before measurement. Pulse wave forms were obtained transcutaneously from the right 
common carotid artery and femoral artery. Aortic PWV was calculated by dividing the 
distance travelled by the time travelled. The time travelled was obtained by measuring 
the time difference between the arrival of the pulse wave at the femoral and carotid 
arteries. The distance travelled (DT) was estimated as 80% of the direct tape measure 
distance between carotid and femoral artery. Carotid-femoral PWV was calculated as 
distance (DT) in meters divided by transit time (TT) in seconds (PWV = DT/TT). The 
mean of two measurements was calculated and when the difference between them was 
more than 0.5 m/s, a third measurement was obtained. All PWV values were adjusted 
by mean arterial pressure (MAP) to obtain normalized PWV (PWV norm) as 100 x 
(PWV/MAP). 
 
 
Central Hemodynamic Parameters 
Applanation tonometry was performed with the SphygmoCor system (Atcor 
Medical, Sydney, Australia) with the patient in the sitting position, resting the arm on a 
rigid surface, and a sensor in the radial artery. Central aortic pressure was calculated 
from the radial pulse wave analysis with the use of a validated transfer function. Wave 
reflection parameters, such as augmentation pressure (AP) and augmentation index 
(AIx), were also obtained by this method. 
 
Carotid Ultrasound Scan 
The patient was supine with slight hyperextension and rotation of the neck in the 
direction opposite the probe. A linear array transducer with a multiple-frequency (7–12 
MHz) attached to a high-resolution B-mode ultrasound system was used to acquire 
images by a single sonographer blind to clinical data of subjects. Simultaneous 
electrocardiogram was recorded to assure the timing of end-diastolic images. Manual 
measurement of intima-media thickness (IMT) was performed in the common carotid 
artery, at both sides, in a region free of plaque located approximately 20 mm from bulb. 
At least three values were obtained in different sites of this segment, and the mean value 
of six measurements (three from each side) was used for analysis. 
 
Statistical analysis 
 Continuous variables were expressed as mean ± standard deviation. Baseline 
differences between the two study groups were evaluated with Student t-tests for 
continuous variables and Fisher's exact test for categorical variables. For intra-group 
comparisons between the baseline and study-end, paired t-test was used. Between-group 
differences were compared using unpaired t-test or Mann–Whitney U-test where 
appropriate. To identify possible relationships between the changes in the study 
parameters, bivariate correlation Pearson coefficients (r) were calculated. A P value 
<0.05 was considered statistically significant. Statistical analysis was performed using 
the Statistical Package for Social Sciences (SPSS) version 18.0 for Windows (SPSS, 
Chicago, IL, USA). 
 
 
Results  
Fifty-three hypertensive women treated with thiazides were screened for this 
study. After initial evaluation, 16 patients were not included due to BP < 130/80 mmHg 
and two other patients had fasting plasma glucose higher than 126 mg/dl and were also 
excluded. 
Baseline clinical characteristics in the placebo and magnesium groups are 
presented in Table 1. The mean age and anthropometric data were not significantly 
different, and both groups presented intermediate risk prediction for general 
cardiovascular disease with normal liver and renal function. The magnesium group 
demonstrated a significant reduction in office systolic and diastolic BP between baseline 
and 6-month evaluation, and a slight decrease in mean 24-h systolic and diastolic BP but 
without statistical significance. The same was observed in both daytime and nigh-time 
periods. The changes in systolic and diastolic BP nocturnal fall were not significantly 
different between the groups (Table 2). 
Fasting plasma glucose, insulin and HOMA indexes were similar at baseline and 
final evaluation in both groups (Table 3). Total cholesterol was significantly decreased at 
the end of the study in the magnesium group. In this group, HDL-cholesterol was 
increased and LDL-cholesterol was reduced but did not reach statistical significance. 
There were no significant changes in the lipid profile in the placebo group. With regards 
to plasma electrolytes, there was a small but significant reduction in serum sodium in the 
placebo group but not in the magnesium group. Serum potassium and calcium were not 
significantly different in both groups. Serum magnesium was significantly reduced in the 
placebo group and did not change in the supplementation group. On the other hand, 
intracellular and urinary magnesium were significantly increased only in the group 
receiving supplementation (Figures 1a-1c). Although there was no significant difference 
in intracellular sodium between the groups, there was a negative correlation between 
intracellular magnesium and intracellular sodium (r=-0.48, p=0.023; Figure 1d). 
 Vascular results are shown in Table 4. Carotid-femoral PWV was similar 
between the groups in baseline and after 6-month supplementation even after adjusting 
for MAP. Likewise, the central hemodynamic parameters were not significantly 
different between the groups before and after intervention. The brachial FMD was 
reduced in the placebo group and increased in the magnesium supplemented subjects 
although not statistically significant. However, the magnesium group presented 
significantly higher values and changes of brachial FMD after supplementation when 
compared to the control group (Figure 2a). The variation of intracellular magnesium 
was positively correlated to the variation (r=0.40, p=0.015) and to the end-study values 
(r=0.44, p=0.011) of brachial FMD (Figures 2c-2d). RHI obtained by peripheral arterial 
tonometry was also reduced in the placebo group and increased in the magnesium group 
but without statistical significance (Figure 2b). After 6 months of study, the placebo 
group demonstrated a small but significant increase in carotid IMT and media-to-lumen 
ratio which were not changed in the magnesium supplemented patients (Figures 3a-3b). 
Serum magnesium was inversely correlated to mean (r=-0.37, p=0.046) and maximum 
(r=-0.52, p=0.004) carotid IMT (Figures 3c-3d). 
Discussion 
 
The therapeutic value of magnesium supplementation for human hypertension is 
still unclear , with some studies showing benefit and others failing to demonstrate 
therapeutic advantage on BP control [30, 31]. In the present study, oral magnesium 
supplementation for six months significantly decreased office systolic and diastolic BP 
in hypertensive women. On the other hand, there was a small and non-statistically 
significant lowering of 24-h BP levels after magnesium supplementation. Nevertheless, 
the reduction of 5 mmHg in systolic and diastolic BP might be clinically relevant 
concerning the prevention of cardiovascular events such as myocardial infarction and 
stroke. This finding is in agreement with a recent meta-analysis that demonstrated a 
small but clinically significant decrease, around 3 mmHg, in systolic and diastolic BP 
determined by magnesium supplementation [32]. In fact, a previous meta-analysis had 
already detected dose-dependent BP reductions from magnesium supplementation [33]. 
Recently, a slight but significant lowering effect of oral magnesium supplementation on 
24-h BP levels was observed in patients with mild hypertension and this finding was 
associated with increase in the intracellular magnesium [34]. 
Heterogeneity in study design, study participants and the type of magnesium 
supplement used could help to explain the different results in several clinical protocols 
regarding the BP lowering effects of magnesium supplementation. Absorption of 
magnesium varies from different kinds of supplements. Hence, some forms of 
administered magnesium may have had lower bioavailability, which might reduce the 
influence on BP levels. Small studies have found that citrate and chloride forms are 
more absorbed than magnesium oxide and sulfate. Chelated magnesium is more likely 
to survive the passage from the stomach to the small intestines intact. Therefore, the 
chelated magnesium bioavailability seems to be higher than other preparations [35]. 
Magnesium is involved in the physiological pathways that regulate glucose and lipid 
metabolism. A growing body of evidence derived from clinical trials shows that oral 
magnesium supplements improve insulin sensitivity and dyslipidemia in diabetic and 
non-diabetic individuals [7, 31, 36]. Insulin resistance is inversely correlated with HDL-
cholesterol levels and atherogenic changes characterized by low HDL-cholesterol are 
mainly seen in insulin-resistant subjects [37]. Magnesium deficiency may be associated 
to low HDL-cholesterol in the prediabetic state and chronic magnesium 
supplementation can contribute to an improvement in islet b-cell response and insulin 
action [38], and is useful in the treatment of hyperlipidemia [39] increasing the HDL-
cholesterol levels [7, 40]. Serum magnesium levels have been correlated with total and 
HDL-cholesterol in a large adult study population [41]. Interestingly, the relationship 
between magnesium status and lipids in healthy individuals may be different from that 
in patients with chronic conditions, such as obesity, diabetes, and hypertension [42, 43]. 
In this study, patients in the magnesium group demonstrated a beneficial effect with a 
significant decrease in total cholesterol, and a non-significant increase in HDL-
cholesterol and reduction in LDL-cholesterol compared to no significant changes in the 
lipid profile in placebo group.  
There was a small but significant reduction in serum sodium and intracellular 
sodium in the placebo group, with a negative correlation between intracellular 
magnesium and intracellular sodium. These findings could indicate a protective effect of 
magnesium on hyponatremia induced by diuretic treatment. Although the mechanisms 
were not investigated in the present study, the Na+/Mg2+ antiport has been previously 
confirmed in mammalian cells [44], and changes in intracellular magnesium could also 
modify transmembrane calcium movements [45]. 
Low urinary magnesium excretion has been previously associated with an increased 
risk of ischemic heart disease [46]. In addition, urinary magnesium excretion can 
estimate the amount of absorbed magnesium, considering that renal elimination is 
highly relevant for an adequate magnesium homeostasis. Chronic intervention studies 
are usually associated to lost of follow-up and low treatment compliance. In the present 
study, both groups presented normal renal function indicating no influence on 
magnesium excretion. Therefore, the increase in intracellular and urinary magnesium in 
the group receiving 6-month supplementation points out the good compliance by these 
patients. Indeed, the increase in the intracellular ion concentrations has already been 
associated with BP lowering effect of oral magnesium supplementation [34].  
  In this study, magnesium supplementation was not able to change arterial 
stiffness and wave reflection parameters. In contrast, we recently demonstrated that low 
intracellular magnesium was associated with more intense wave reflection [47]. 
Likewise, it has been previously demonstrated that serum magnesium levels were 
associated with augmentation index although not with PWV. However, the cross-
sectional design and the oscilometric method used in that study to evaluate arterial 
stiffness and pulse wave reflection may be considered as limitations of those findings 
[48]. 
Endothelial dysfunction has been suggested to represent an early indicator of 
atherosclerosis, associated with an increased incidence of vascular diseases. Past studies 
have demonstrated that low magnesium promotes endothelial cell dysfunction [49] and 
endothelium-dependent relaxation induced by extracellular magnesium is mediated by 
NO release by the endothelium [50]. The results of the present study demonstrated the 
beneficial effects of oral magnesium supplementation on endothelial function, including 
the positive correlation between variation of intracellular magnesium and brachial 
FMD. One of the possible mechanisms is that magnesium affects calcium ion 
concentrations and its availability at critical sites, acting as a physiologic calcium 
channel blocker [51]. Although not directly involved in the biochemical process of 
contraction, magnesium influences vascular tone, baseline tension and vascular 
responsiveness to vasoconstrictor agents, both via endothelium independent and 
endothelium dependent pathways [52, 53]. Our results are in accordance with previous 
report that oral magnesium supplementation resulted in a significant improvement in 
brachial artery endothelial function in elderly diabetic patients [12] and in patients with 
coronary artery disease [54]. 
Magnesium deficiency has been introduced as a cardiovascular risk factor, and 
some studies have shown that hypomagnesemia is associated with atherosclerosis [55, 
56]. Our data demonstrated an increase in carotid IMT in the placebo group while 
hypertensive women receiving magnesium supplementation presented no difference. 
This result might be attributed to higher blood pressure levels in the placebo group. In 
accordance with these findings, a recent study in hemodialysis patients showed that 
magnesium oxide for 6 months was able to decrease carotid IMT with an increase in the 
placebo group [57]. Indeed, the role of magnesium in attenuating the progression of 
atherosclerosis has been previously demonstrated in hemodialysis patients [58]. 
Some limitations warrant consideration in the present study. The beneficial effect of 
magnesium on endothelial function may be considered the main finding but we did not 
study  all biochemical endothelial markers. Moreover, there was no concomitant 
assessment of endothelium-independent dilation. On the other hand, in our experimental 
model, all the results were compared to a control, not supplemented group, and there 
was no improvement in brachial FMD in these patients receiving placebo. Lastly, the 
single investigator performing the exams was blinded to the treatment assigned. 
 The significant magnesium effects in our study may relate, in part, to the fact 
that, unlike other studies, we investigated only female patients on thiazide diuretics, 
who are at particular risk of magnesium wasting. In fact, the recommended dietary 
allowance (RDA) for magnesium is different for middle-aged men (420mg/day) and 
women (320mg/day). Considering the study design as a randomized, double blind, 
clinical trial, we enrolled only hypertensive women in order to avoid this gender 
difference as a confounding factor. Hence, this patient cohort may indeed benefit from 
magnesium supplementation with respect to blood pressure control and vascular 
protection. The effects of sex steroid hormones on magnesium metabolism and actions 
are not clear yet. Nevertheless, this concern is not relevant in this study since almost all 
patients were postmenopausal women. 
In conclusion, 6-month magnesium supplementation was able to lower BP, 
attenuate subclinical atherosclerosis and improve endothelial function in hypertensive 
women on thiazide treatment. The beneficial effects of magnesium supplementation 
may be more evident in patients with a negative magnesium balance. Since magnesium 
is an inexpensive, natural, and relatively safe element, its possible role as adjuvant 
therapy in those subjects who are at high risk of magnesium deficiency should be 
considered. There is still considerable uncertainty on the clinical utility of magnesium 
supplements. Therefore, further studies with larger populations are needed to confirm 
our findings. 
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Table 1. Clinical characteristics of the study groups. 
Parameters 
Placebo 
(n=18) 
Magnesium 
(n=17) 
P value 
Age, years 57 ± 5 54 ± 7 0.571 
Menopause, n (%) 16 (88.9) 17 (100) 0.357 
Current smoker, n (%) 1 (5.5) 1 (5.9) 1.000 
BMI, kg/m2 26.8 ± 3.9 29.7 ± 4.1 0.311 
Waist, cm 92.2 ± 10.9 98.3 ± 9.9 0.259 
WHR, units 0.84 ± 0.39 0.84 ± 0.63 0.991 
General CV risk, % 14.5 ± 7.3 14.2 ± 8.5 0.228 
Creatinine, mg/dl 0.78 ± 0.16 0.76 ± 0.12 0.946 
AST, U/l 19.8 ± 0.7 19.0 ± 1.5 0.809 
ALT, U/l 18.6 ± 1.3 19.4 ± 1.4 0.820 
The values are expressed as mean ± SD. BMI, body mass index; WHR, waist-to-hip 
ratio; CV, cardiovascular; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase. 
 
 
 
Table 2. Office and ambulatory blood pressure levels in placebo and magnesium 
supplementation groups. 
 Placebo (n=18) Magnesium (n=17) Between- 
group 
comparison 
P value * 
 
Parameters Baseline Final 
P 
value 
Baseline Final 
P 
value 
Office SBP, mmHg 143 ± 16 142 ± 18 0.635 144 ± 17 134 ± 14 0.036 0.240 
Office DBP, mmHg 86 ± 10 86 ± 9 0.760 88 ± 9 81 ± 8 0.005 0.172 
SBP-24h, mmHg 134 ± 11  135 ± 13  0.168 135 ± 11 129 ± 11 0.074 0.322 
DBP-24h, mmHg 86 ± 8  84 ± 7  0.076 86 ± 6 81 ± 10 0.111 0.472 
PP-24h, mmHg 48 ± 9 51 ± 9 0.548 49 ± 9 50 ± 12 0.871 0.811 
Systolic load, % 54 ± 27 53 ± 29  0.191 57 ± 32 47 ± 34  0.190 0.678 
Diastolic load, % 65 ± 23 57 ± 23  0.221 68 ± 20 50 ± 32 0.109 0.597 
Daytime SBP, mmHg 140 ± 11  137 ± 15  0.148 139 ± 11 133 ± 11 0.097 0.466 
Daytime DBP, mmHg 91 ± 9  87 ± 8  0.051 90 ± 7 85 ± 10 0.087 0.557 
Night-time SBP, mmHg 131 ± 18  130 ± 11  0.383 126 ± 14 123 ±  12 0.195 0.258 
Night-time DBP, mmHg 80 ± 9  77 ± 7  0.299 77 ± 8 75 ± 9 0.231 0.605 
SBP nocturnal fall, % 6.3 ± 7.1 5.2 ± 7.3 0.878 10.1 ± 5.4 7.3 ± 5.6 0.487 0.558 
DBP nocturnal fall, % 11.8 ± 7.8 11.7 ± 6.4 0.998 14.5 ± 7.1 11.5 ± 5.7 0.430 0.951 
The values are expressed as mean ± SD. SBP, systolic blood pressure; DBP, diastolic 
blood pressure; PP, pulse pressure. * Student t-test for between groups comparison at the 
end of the study. 
Table 3. Biochemical profile at baseline and study-end in the placebo and magnesium 
supplementation groups.  
 Placebo (n=18) Magnesium (n=17) Between- 
group 
comparison 
P value  
Parameters Baseline Final 
P 
value 
Baseline Final 
P 
value 
Glucose, mg/dl 90 ± 12 96 ± 11 0.428 93 ± 8 91 ± 10 0.270 0.346 
Insulin, mcU/ml 12.8 ± 8.9 12.8 ± 11.1 0.949 11.2 ± 3.9 10.7 ± 3.8 0.733 0.596 
HOMA-IR 2.9 ± 2.2 2.8 ± 2.6 0.832 2.6 ± 1.1 2.4 ± 0.9 0.719 0.675 
HOMA-beta 176 ± 106 139 ± 161 0.289 141 ± 48  184 ± 168 0.361 0.586 
Total cholesterol, 
mg/dl 
223 ± 36 220 ± 38 0.244 241 ± 56 216 ± 32 0.038 0.816 
HDL-cholesterol, 
mg/dl 
54 ± 14 50 ± 13 0.052 58 ± 17 62 ± 15 0.720 0.126 
LDL-cholesterol, 
mg/dl 
146 ± 32 144 ± 32 0.541 155 ± 39 126 ± 31 0.058 0.253 
Triglycerides, mg/dl 117 ± 57 129 ± 60 0.664 111 ± 60 114 ± 55 0.102 0.582 
Serum Na, mEq/l 142 ± 2 140 ± 2 0.046 140 ± 3 140 ± 3 0.456 0.536 
Serum K, mEq/l 4.2 ± 0.3 3.9 ± 0.3  0.384 4.2 ± 0.4 4.1 ± 0.3  0.601 0.410 
Serum Ca, mg/dl 9.3 ± 0.5 9.6 ± 0.4 0.516 9.7 ± 0.9 9.4 ± 0.5 0.317 0.253 
Serum Mg, mg/dl 2.1 ± 0.2 1.9 ± 0.2 0.048 2.1 ± 0.2 2.1 ± 0.2  0.756 0.029 
UMCR, g/g 0.05 ± 0.02 0.05 ± 0.02 0.620 0.05 ± 0.02 0.12 ± 0.07 0.057 0.018 
ic Mg, mg/dl eryt 4.27 ± 0.64 4.06 ± 0.52 0.101 4.05 ± 0.61 4.75 ± 0.56 0.001 0.005 
ic Na, mg/dl eryt 23 ± 9 18 ± 6 0.504 21 ± 9 20 ±  3 0.343 0.585 
The values are expressed as mean ± SD. * Paired t-test for intra-group analysis. ** Student t-test for 
independent analysis between the groups. HOMA IR, Homeostatic Model Assessment - Insulin Resistance, 
HOMA Beta, Homeostatic Model Assessment Beta Cell Function; HDL, high density lipoprotein, LDL, 
low density lipoprotein; UMCR, urinary magnesium creatinine ratio; ic, intracellular; eryt, erythrocytes. 
Table 4. Comparison of vascular tests between the groups.  
 
 Placebo (n=18) Magnesium (n=17) Between- 
group 
comparison 
P value * 
 
Parameters Baseline Final 
P 
value 
Baseline Final 
P 
value 
Brachial FMD, % 8.3 ± 5.3 5.8 ± 3.7 0.064 8.3 ± 5.6 11.9 ± 6 0.109 0.008 
RHI, units 1.96 ± 0.36 1.85 ± 0.56 0.708 1.93 ± 0.30 2.09 ± 0.49 0.374 0.326 
PWV, m/s 8.24 ± 1.28 8.16 ± 0.88  0.781 8.24 ± 1.12 8.08 ± 1.04 0.605 0.801 
PWVnorm, m/s 7.92 ± 1.28 8.16 ± 1.12 0.610 7.76 ± 1.20 7.68 ± 1.04 0.819 0.321 
AP, mmHg 19 ± 6 19 ± 4 0.960 18 ± 5 18 ± 7 0.920 0.597 
AIx, % 38 ± 9 39 ± 2 0.721 38 ± 4 36 ± 7 0.260 0.158 
AIx@75, % 36 ± 9 35 ± 3 0.798 33 ± 3 32 ± 6 0.595 0.263 
Aortic SBP, mmHg 131 ± 15 130 ± 16 0.756 130 ± 14 129 ± 13 0.897 0.915 
Aortic PP, mmHg 46 ± 11 47 ± 10 0.577 46 ± 11 45 ± 14 0.878 0.503 
Mean carotid IMT, mm 0.78 ± 0.13 0.89 ± 0.14 0.033 0.79 ± 0.16 0.79 ± 0.19 0.716 0.282 
Max carotid IMT, mm 0.99 ± 0.35 1.13 ± 0.30 0.156 0.92 ± 0.19 0.93 ± 0.24  0.681 0.169 
Carotid media-lumen 
ratio, mm 
0.11 ± 0.01 0.13 ± 0.02 0.011 0.11 ± 0.02 0.11 ± 0.03 0.917 0.036 
All values are expressed as mean±SD. FMD, flow-mediated dilation; RHI, reactive hyperemia index; PWV, 
pulse wave velocity; PWVnorm, pulse wave velocity normalized for mean arterial pressure; AP, 
augmentation pressure; AIx, augmentation index; AIx@75, augmentation index corrected for heart rate of 
75 bpm; SBP systolic blood pressure; PP, pulse pressure, IMT, intima-media thickness. * Paired t-test for 
intra-group analysis. ** t test for inter-group analysis. 
 
 
Figure legends 
 
Figure 1. Changes in serum (A), urinary (B) and intracellular (C) magnesium in the study 
groups. Correlation between intracellular (ic) magnesium and sodium (D). 
 
 
 
Figure 2. Changes in brachial flow-mediated dilation (FMD) (A) and in reactive 
hyperemia index (RHI) by peripheral artery tonometry (B) in both groups. Correlation of 
changes in intracellular (ic) magnesium with study-end values of brachial FMD (C) and 
with changes in brachial FMD (D) after 6 months of study. 
 
 
 
Figure 3. Changes in carotid intima-media thickness (IMT) (A) and in carotid media-
lumen ratio (B) in the placebo and magnesium groups. Correlation of serum magnesium 
with mean carotid IMT (C) and with maximum carotid IMT (D). 
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Figure Click here to download Figure Figure3.tif 
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Manuscript 
 
“Oral magnesium supplementation improves endothelial function and attenuates subclinical 
atherosclerosis in thiazide-treated hypertensive women” 
  
Response to Reviewers 
 
We thank the reviewers for their thoughtful review. We have revised the manuscript in 
accordance to all the points raised by the criticisms of the reviewers. We believe that this 
has resulted in a significant improvement of the manuscript and the clarity with which it is 
presented. 
 
Reviewer 1: 
This is an interesting study, showing a significant correlation between the intracellular 
magnesium variation and FMD (r=0.44, p=0.011) in hypertensive women. Magnesium 
supplementation was associated with better BP control, improved endothelial function and 
amelioration of IMT.  
  
Q1. The manuscript is well written, pending on the lacked information on renal and liver 
functions. Both can deeply influence the rate of magnesium absorption/excretion. Thus, it is 
necessary to show data on liver and renal function in the appropriate table (n.1). 
A1: We completely agree with this referee's observation. Indeed, serum creatinine 
values were reported in the second paragraph of “Results” indicating normal renal 
function in both groups. As the study population consisted of middle-aged women and 
serum creatinine levels were normal, it was not necessary to estimate GFR to show 
normal renal function. All the patients presented normal liver function. Considering 
the relevance of this comment, we included the values of creatinine, AST and ALT in 
Table 1. We also included a comment about this issue in Discussion: “In the present 
study, both groups presented normal renal function indicating no influence on 
magnesium excretion.” 
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Reviewer 2  
In this randomized, double-blind study, the authors assessed the effect of 6-month 
magnesium supplementation on blood pressure (BP) and vascular function in thiazide-
treated hypertensive women. Magnesium supply reduced office BP, ameliorated FMD and 
lipid profile, while unaffecting plasma glucose, arterial stiffness or IMT parameters. In 
contrast, the placebo-group showed a significant increase in carotid IMT. The authors 
concluded that magnesium supplementation was associated with better BP control, 
improved endothelial function and amelioration of atherosclerosis in the thiazide-treated 
hypertensive women. 
 
 
Q1. It is not clear the cardiovascular risk profile of the women recruited. The smoking 
history, as well as the estimated GFR are missing. The latter is crucial, when considering 
that magnesium is eliminated by urine.  
A1. We agree with the referee's point of view. Indeed, cardiovascular risk is shown in 
table 1 pointing out an intermediate profile. There was only 1 smoker in each group. 
We added this information in Table 1. Serum creatinine values were reported in the 
second paragraph of “Results” indicating normal renal function in both groups. 
Considering the relevance of this comment, we included the values of creatinine in 
Table 1. As the study population consisted of middle-aged women and serum 
creatinine levels were normal, it was not necessary to estimate GFR to show normal 
renal function. We also included a comment about this issue in Discussion: “In the 
present study, both groups presented normal renal function indicating no influence on 
magnesium excretion.”  
 
Q2. 2. The authors recognize the recruitment of women as a limitation of the present study. 
It is not clear why the authors excluded men. It is because women, but not men, undergo to 
hypomagnesemia under diuretic intake? 
A2. The point raised by the referee is completely appropriate. In fact, women and men 
are candidates to hypomagnesemia under diuretic therapy. However, the 
recommended dietary allowance (RDA) for magnesium is different for middle-aged 
men (420mg/day) and women (320mg/day). As the study design was a randomized, 
double blind, clinical trial, we enrolled only hypertensive women in order to avoid this 
gender difference as a confounding factor. We recognized this consideration and we 
added this comment in Discussion, one before the last paragraph.  
 
 
Q3. It is interesting that magnesium supply does not affect vascular atherosclerosis. 
However, it is quite surprising that 6 months of placebo might induce a significantly 
progression of IMT in middle-aged women. Is this the unique effect of uncontrolled BP? 
The authors should better clarify this aspect.  
A3. We agree with the referee's observation. Indeed, we believe that this finding was 
related to higher blood pressure levels in the placebo group. Thus, we added this 
comment in Discussion: “Our data demonstrated an increase in carotid IMT in the 
placebo group while hypertensive women receiving magnesium supplementation 
presented no difference. This result might be attributed to higher blood pressure 
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levels in the placebo group. In accordance with these findings, a recent study in 
hemodialysis patients showed that magnesium oxide for 6 months was able to decrease 
carotid IMT with an increase in the placebo group.” 
 
 
Q4. Have the authors any idea on the possibility the estrogen/progestin might play a role on 
the magnesium-induced impact on these parameters? 
A4. This is an interesting question raised by the referee and we agree with this 
concern. “The effects of sex steroid hormones on magnesium metabolism and actions 
are not clear yet. Nevertheless, this concern is not relevant in this study since almost 
all patients were postmenopausal women.” We added these sentences in Discussion, 
one before the last paragraph. 
 
 
